Unternehmensübersicht
Voyager Therapeutics, Inc. operates as a specialized biotechnology enterprise dedicated to leveraging human genetics to develop curative therapies for neurological disorders. The company's product pipeline features specific assets such as VY1706, a tau silencing gene therapy, and VY7523, an anti-tau antibody program designed for the treatment of Alzheimer's disease. Within the broader Healthcare sector, the firm functions specifically within the Biotechnology industry, focusing on high-risk, high-reward therapeutic development rather than immediate consumer goods or services. As of the latest reporting period, the company holds a market capitalization of $233.63M, generates annual revenue of $40.37M, and employs a workforce of 141 individuals. These financial figures indicate that Voyager Therapeutics maintains a relatively small market footprint typical of early-stage biotech firms that prioritize research and development expenditures over profit generation, positioning the entity as a specialized player in the genetic medicine landscape rather than a large-cap diversified pharmaceutical corporation.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $40.37M, yet this top-line performance contrasts sharply with a net income of $-119,721,000 and an EBITDA of $-124,284,000. The substantial gap between the positive revenue and the deeply negative net income reveals a cost structure characterized by extreme operating expenses, likely driven by the intensive R&D requirements inherent to gene therapy development and clinical trial costs. Free cash flow stands at $-83,939,000, indicating that the company is consuming cash reserves to fund its operational activities and growth initiatives rather than generating liquidity from its core business. Despite these outflows, the balance sheet retains a significant cash position of $196.45M against total debt of $36.50M, suggesting a conservative liquidity posture with substantial net cash available to fund operations or future acquisitions. The debt-to-equity ratio of 18.61 reflects the weighted nature of the company's capital structure, while the current ratio of 7.64 demonstrates robust short-term liquidity, ensuring the firm can comfortably meet its immediate obligations. Furthermore, the Return on Equity of -48.3% and Return on Assets of -24.9% highlight that management is currently deploying capital to generate value that has not yet translated into profitability, a common pattern for pre-commercial biotechnology entities. The negative margins across the board further underscore this developmental phase: a Gross Margin of -227.6%, an Operating Margin of -172.4%, and a Profit Margin of -296.5% collectively illustrate the intense burn rate required to advance a complex scientific pipeline to market approval.
Bewertungsanalyse
Valuation metrics for Voyager Therapeutics reflect its lack of historical profitability, resulting in a P/E Ratio (TTM) of N/A and a Forward P/E of -2.29. The absence of a trailing P/E and the negative forward multiple imply that traditional earnings-based valuation models are not applicable, as the market is pricing the stock based on potential future earnings rather than current or projected annual profits. The Price to Book ratio stands at 1.18, indicating that the market values the company at a slight premium over its tangible book value, which is typical for firms with valuable intellectual property that may not be fully reflected on the balance sheet. Alternative valuation metrics such as the Price to Sales ratio of 5.79 and the EV/EBITDA of -0.59 suggest that investors are placing a high multiple on revenue, anticipating significant future scale once the product pipeline matures. In terms of trading range, the stock has fluctuated between a 52-Week High of $5.55 and a 52-Week Low of $2.65. Without a specific current price provided in the source data, the valuation context relies on these historical bounds to understand the volatility envelope within which the stock has traded over the past year. The Beta of 1.38 indicates that the stock price is significantly more volatile than the broader market, moving with greater intensity to reflect the high-risk nature of biotechnology investments.
Growth & Income
Revenue growth demonstrates strong momentum with a Year-over-Year increase of 144.3%, signaling rapid expansion in sales or licensing deals. Earnings growth is listed as N/A due to the company's continued net losses, which means earnings are not yet growing at a positive rate but rather moving from larger losses toward breakeven. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, reflecting a strategy where all available earnings are reinvested into research, development, and operational scaling rather than distributed to shareholders. The overall growth and income profile is defined by aggressive revenue expansion funded entirely by internal cash reserves and external financing, with no reliance on shareholder dividends to support investor returns. This reinvestment approach is standard for biotechnology companies in the development phase, where capital deployment is directed exclusively toward advancing the VY1706 and VY7523 programs and other pipeline assets toward clinical validation and commercialization.